Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 1.00 |
| ▸ | CNR2 | P34972 | 5/20 | 1.00 |
| ▸ | KDR | P35968 | 3/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delta-8-Tetrahydrocannabinol SCHEMBL29360992 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31545578 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31545313 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31315116 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL2800340 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL24237019 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL12054803 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL2762327 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL31236168 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR | |
| Delta-8-Tetrahydrocannabinol SCHEMBL29361531 | 1.00 | CNR1 (1.00) | CNR1CNR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2016-03-17 | — | — | US | claimed |
| US-9186386-B2 | Pharmaceutical composition and method of manufacturing | SINDERBRAND LAW GROUP, PC | 2015-11-17 | — | — | US | claimed |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | SINDERBRAND LAW GROUP, PC | 2015-10-22 | — | — | US | claimed |
| US-20260077009-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Neurotech International Ltd (AU) | 2026-03-19 | — | — | US | disclosed |
| US-20260069618-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | EPM GROUP INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-3894036-B1 | EXTRACTION METHOD | NATURALIA INGREDIENTS S R L (IT) | 2026-01-14 | — | — | EP | disclosed |
| US-20250380732-A1 | AEROSOLISABLE FORMULATION | NICOVENTURES TRADING LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-12491452-B2 | Extraction method and composition obtained therefrom | NATURALIA INGREDIENTS S.R.L. (IT) | 2025-12-09 | — | — | US | disclosed |
| US-20250262261-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | Neurotech International Ltd (AU) | 2025-08-21 | — | — | US | disclosed |
| US-20250064713-A1 | COSMETIC COMPOSITIONS | ELEBLEND LLC (US) | 2025-02-27 | — | — | US | disclosed |
| EP-0650483-A1 | (3R,4R)-$g(D)?6 -TETRAHYDROCANNABINOL-7-OIC ACIDS | BURSTEIN, Sumner (US) | 1995-05-03 | — | — | EP | disclosed |
| US-5338753-A | (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics | Burstein, Sumner H. (US) | 1994-08-16 | — | — | US | disclosed |
| WO-1994001429-A1 | (3R,4R)-Δ6-TETRAHYDROCANNABINOL-7-OIC ACIDS | BURSTEIN SUMNER H (US) | 1994-01-20 | — | — | WO | disclosed |
| US-4973603-A | 6A,7,10,10A-TETRAHYDRO-6,6-DIMETHYL-9-CARBOXYL-3-PENTYL-6H -DIBENZO/B,D/PYRAN-1-OL | ENDO PHARMACEUTICALS SOLUTIONS INC. | 1990-11-27 | — | — | US | disclosed |
| WO-1989012446-A1 | TETRAHYDROCANNABINOL DERIVATIVES AS PLATELET ACTIVATING FACTOR ANTAGONISTS | BURSTEIN SUMNER (US) | 1989-12-28 | — | — | WO | disclosed |
| US-4116979-A | Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans | SHEEHAN INSTITUTE FOR RESEARCH, INC. (US) | 1978-09-26 | — | — | US | disclosed |
| US-4104282-A | ANALGESICS | ELI LILLY AND COMPANY (US) | 1978-08-01 | — | — | US | disclosed |
| US-4064009-A | FERMENTATION WITH BACILLUS CEREUS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064713-A1 | COSMETIC COMPOSITIONS | CUTA, SUCLG1, ASAH2 | CNR1 2691/4885CNR2 2053/4885KDR 4855/4885 |
| US-20260069618-A1 | CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF | CNR2, CNR1, IL17A | CNR1 2/4885CNR2 1/4885KDR 2392/4885 |
| US-20260077009-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | CNR2, CNR1, SNCA | CNR1 2/4885CNR2 1/4885KDR 4041/4885 |
| US-20160074451-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR1 2/4885CNR2 1/4885KDR 2860/4885 |
| US-20150297654-A1 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING | CNR2, CNR1, CYP3A5 | CNR1 2/4885CNR2 1/4885KDR 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.